Abstract:Background: Human osteosarcoma is the most common primary cancer of the bone. Multiple mechanisms underlying cell growth, apoptosis, bone development, and drug resistance are important in the development of osteosarcoma therapy, which remains to be fully studied. Methods: We collected thirty-paired tumor tissues and the adjacent normal ones from osteosarcoma patients. Two osteosarcoma cell lines (SAOS2, U2OS) were used for in vitro experiments. RT-qPCR and Western blot were used for gene expression detection. We applied starBase to predict the potential binding sites. Then, the luciferase reporter assay was used to confirm the potential direct interaction. Besides, we applied CCK-8, EdU assay, and flow cytometric assays to detect cell growth and apoptosis rate. We used wound healing and transwell assays to determine cell migration and invasion abilities. Additionally, we constructed a cisplatin-resistant osteosarcoma cell line to study the potential impact of the regulatory axis on drug resistance. Results: Small nucleolar RNA host gene 16 (SNHG16) and autophagy-related 4B (ATG4B) were significantly upregulated in osteosarcoma tissues than the normal ones, and the higher expression level of SNHG16 predicted a poor prognosis in osteosarcoma patients. By contrast, the expression level of miR-16 was markedly lower in tumor tissues and was negatively correlated with SNHG16 (p < 0.001). SNHG16 was shown to promote cell growth, migration, and invasion, while miR-16 reversed this impact. Meanwhile, overexpression of ATG4B significantly promoted the development of osteosarcoma cells attenuated by SNHG16 knockdown or miR-16 mimics. Specifically, overexpression of ATG4B promoted cisplatin-induced autophagy and inhibited cell apoptosis rate, which enhanced the cisplatin resistance in osteosarcoma cell lines. Conclusions: Overall, our findings showed the importance of the regulatory axis of SNHG16/miR-16/ ATG4B underlying osteosarcoma progression and chemoresistance to cisplatin. This research would benefit the therapy development in the treatment of osteosarcoma. (C) 2019 Elsevier Inc. All rights reserved.

P21 Overexpression Sensitizes Osteosarcoma U2OS Cells to Cisplatin Via Evoking Caspase-3 and Bax/Bcl-2 Cascade.

Synergistic Apoptotic Effect of Crocin and Cisplatin on Osteosarcoma Cells Via Caspase Induced Apoptosis.

Recombinant antisense C-myc adenovirus increase in vitro sensitivity of osteosarcoma MG-63 cells to cisplatin.

Antisense C - Myc Sensitizes Osteosarcoma Cells to Cisplatin- Induced Apoptosis

Checkpoint Kinase Inhibitor AZD7762 Enhance Cisplatin-Induced Apoptosis in Osteosarcoma Cells.

Silencing Of Barkor/Atg14 Sensitizes Osteosarcoma Cells To Cisplatin-Induced Apoptosis

Activation of Unfolded Protein Response Protects Osteosarcoma Cells from Cisplatin-Induced Apoptosis Through NF-κB Pathway.

P-Glycoprotein Overexpression is Associated with Cisplatin Resistance in Human Osteosarcoma

Celecoxib Enhances Anticancer Effect of Cisplatin and Induces Anoikis in Osteosarcoma Via PI3K/Akt Pathway.

[Cytotoxic Effect of Cisplatin with Proteasome Inhibitor on Osteosarcoma Cells].

PINK1 regulates apoptosis of osteosarcoma as the target gene of cisplatin

Targeting Notch1 signaling pathway positively affects the sensitivity of osteosarcoma to cisplatin by regulating the expression and/or activity of Caspase family

Oleandrin sensitizes human osteosarcoma cells to cisplatin by preventing degradation of the copper transporter 1.

Blockade of survivin promotes the apoptosis of human osteosarcoma cell line U-2OS

Oleandrin synergizes with cisplatin in human osteosarcoma cells by enhancing cell apoptosis through activation of the p38 MAPK signaling pathway

Suppression of Osteosarcoma Cells Growth by 3-Aminobenzamide Combined with Cisplatin

SNHG16 Promotes Osteosarcoma Progression and Enhances Cisplatin Resistance by Sponging Mir-16 to Upregulate ATG4B Expression.

P53 Inhibits CTR1-mediated Cisplatin Absorption by Suppressing SP1 Nuclear Translocation in Osteosarcoma

Enhancing radiosensitivity in osteosarcoma via CDKN2C overexpression: A mechanism involving G1 phase arrest mediated by inhibition of CDK4 expression and Thr172 phosphorylation

Autophagic Degradation of Foxo3a Represses the Expression of Puma to Block Cell Apoptosis in Cisplatin-Resistant Osteosarcoma Cells

Abstract 269: A Novel Mechanism of P21 Induction by Oxaliplatin in P53 Deficient Cancer Cells